-+ 0.00%
-+ 0.00%
-+ 0.00%

ENHERTU® PLUS PERTUZUMAB RECOMMENDED FOR APPROVAL IN THE EU BY CHMP AS FIRST-LINE TREATMENT FOR PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER

路透·07/24/2026 11:00:00

登录查看新闻详情